Title: Animal Imaging Core Recent advances in small animal imaging have substanfially improved our ability to gain insights into disease progression without altering the biological systems. The small animal imaging facility at UNC currentiy houses nine major imaging equipments, including MRI (2), PET/CT (1), CT (1), SPECT (1), optical imaging (3), and ultrasound (1). In addition, skillful technical staff members to maintain and operate the imaging equipments and animal technicians to facilitate animal preparation for imaging and monitoring during imaging are available. Leveraging on these impressive resources, the small animal imaging (SAI) core aims to provide advanced imaging technology to facilitate the proposed projects. Specifically, two major imaging tasks will be carried out for the proposed projects, including to depict biodistribution of nanoparticles (Projects 1, 2, and 3) and to monitor and evaluate therapeutic efficacy of the proposed nanoparticles or treatment regirnens (Projects 2, 3, and 4) using imaging methods. To accomplish the former task, both PET and optical imaging methods will be developed to more efficiently and accurately provide biodistribution informafion. For the latter task, four imaging modalities, including optical, CT, PET, and MRI will be used to monitor therapeufic efficacy. Finally, while the imaging capability in the small animal imaging facility is already impressive, our insfitution has committed additional funds to further augment the imaging program at UNC, including the establishment of an on-site cyclotron facility and the associated radiochemistry lab and the development of imaging registrafion approaches for mulfimodality imaging using microCT, MRI, and PET (Projects 2, 3 and 4). Together, we believe that the available technical expertise and well established infrastructure in the small animal imaging facility will greatly facilitate the success ofthe proposed projects.
The SAI core will provide novel non-invasive imaging approaches for determining bio-distribufion ofthe proposed nanoparticles and monitoring disease progression and therapeutic efficacy. In addition, image analysis tools will be developed to provide quanfitative measures of biological parameters.
|Kim, Junghyun; Luo, Zhi-Xiang; Wu, Yue et al. (2017) In-Situ Formation of Holmium Oxide in Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron-Activatable Radiotherapeutics. Carbon N Y 117:92-99|
|Miao, Lei; Guo, Shutao; Lin, C Michael et al. (2017) Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev 115:3-22|
|Huo, Meirong; Zhao, Yan; Satterlee, Andrew Benson et al. (2017) Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 245:81-94|
|Kim, Junghyun; Narayan, Roger J; Lu, Xiuling et al. (2017) Neutron-activatable needles for radionuclide therapy of solid tumors. J Biomed Mater Res A 105:3273-3280|
|Min, Yuanzeng; Roche, Kyle C; Tian, Shaomin et al. (2017) Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol 12:877-882|
|Goodwin, Tyler J; Huang, Leaf (2017) Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. Vaccine 35:2550-2557|
|Satterlee, Andrew B; Attayek, Peter; Midkiff, Bentley et al. (2017) A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study. Radiat Oncol 12:54|
|Tian, Xi; Nguyen, Minh; Foote, Henry P et al. (2017) CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1?. Cancer Res 77:112-122|
|Goodwin, Tyler J; Shen, Limei; Hu, Mengying et al. (2017) Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials 141:260-271|
|Kim, Junghyun; Jay, Michael (2017) Neutron-activatable radionuclide cancer therapy using graphene oxide nanoplatelets. Nucl Med Biol 52:42-48|
Showing the most recent 10 out of 178 publications